November 14 | 2022
2cureX discloses status of 2022 plans, goals for 2023 and its estimates of potential market development in the coming years
Read more
October 11 | 2022
Independent market survey shows great demand for 2cureX product portfolio
Read more
October 6 | 2022
Co-inventor of 2cureX patents awarded Nobel Prize in Chemistry
Read more
September 19 | 2022
Change of distribution partner in Portugal
Read more
September 1 | 2022
2cureX expands distribution of IndiTreat® to Romania
Read more
August 8 | 2022
Announcement from 2cureX extra general meeting
Read more
August 8 | 2022
Kommuniké från extra bolagsstämma i 2cureX
Read more
June 28 | 2022
2cureX expands distribution of IndiTreat® to Israel
Read more
June 7 | 2022
2cureX AB announces share purchase by the company’s Chairman of the Board of Directors and Executive Management
Read more
May 31 | 2022
Strengthening the IndiTreat® distribution in North Europe
Read more
May 20 | 2022
We invite you to join the 2cureX Q1 Report webcast and Q&A session at 15:00 on 24 May, 2022
Read more
May 17 | 2022
Three IndiTreat® posters have been accepted at ESMO-GI 2022
Read more
May 11 | 2022
IGNITE update – Eight hospitals have been enrolled in the program
Read more
May 9 | 2022
2cureX presents IndiTreat® clinical results at the Society for Functional Precision Medicine
Read more
May 6 | 2022
2cureX appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share
Read more
May 6 | 2022
2cureX utser Sedermera Corporate Finance AB till likviditetsgarant för bolagets aktie
Read more
May 5 | 2022
Redeye research interview with 2cureX CEO, Fernando Andreu
Read more
April 14 | 2022
Chairman of the 2cureX Board exercises all warrants within the framework of the 2018 incentive program
Read more